nivolumab + relatlimab + capecitabine

This is a **combination regimen** consisting of **nivolumab, relatlimab, and capecitabine**, utilized in clinical trials for various cancers. - **Nivolumab** is a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting the programmed death-1 (**PD-1**) receptor, thus reactivating T cells to attack tumor cells. - **Relatlimab** is a monoclonal antibody targeting lymphocyte-activation gene 3 (**LAG-3**), another immune checkpoint, thereby promoting T cell function and enhancing antitumor immunity[1][5]. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), and acts as a cytotoxic antineoplastic agent that inhibits DNA synthesis in rapidly dividing cells[3]. This combination merges immunotherapeutic and chemotherapeutic modalities for potential synergistic effects in tumor control. Nivolumab and relatlimab together are approved as Opdualag for melanoma, while the triple regimen (including capecitabine) is under investigation in triple-negative breast cancer (TNBC) and other solid tumors (clinical trial settings)[3]. The combination is not approved as a triple therapy for any indication but is being studied for efficacy and safety in cancer patients, especially TNBC post-neoadjuvant setting.

Other names

nivolumab + relatlimab + capecitabine